{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sclc&page=15", "query": { "condition": "Sclc", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 4014, "total_pages": 402, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sclc&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sclc&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T14:05:19.430Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07121829", "title": "Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Solid Tumor", "Pilocytic Astrocytoma", "Non Small Cell Lung Cancer", "Colorectal Cancer", "Pancreatic Cancer", "MAP Kinase Family Gene Mutation", "RAS Mutation", "RAF Mutation", "MEK Mutation" ], "interventions": [ { "name": "Tovorafenib", "type": "DRUG" }, { "name": "Tovorafenib Drug: Pimasertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Day One Biopharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 44, "start_date": "2022-05-02", "completion_date": "2024-12-18", "has_results": false, "last_update_posted_date": "2025-08-14", "last_synced_at": "2026-11-07T14:05:19.430Z", "location_count": 8, "location_summary": "Los Angeles, California • Newport Beach, California • Aurora, Colorado + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07121829" }, { "nct_id": "NCT04644237", "title": "Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Trastuzumab deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152, "start_date": "2021-03-19", "completion_date": "2024-08-23", "has_results": true, "last_update_posted_date": "2025-11-21", "last_synced_at": "2026-11-07T14:05:19.430Z", "location_count": 11, "location_summary": "Aurora, Colorado • Orlando, Florida • Tampa, Florida + 6 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04644237" }, { "nct_id": "NCT02576431", "title": "A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors Harboring NTRK Fusion" ], "interventions": [ { "name": "BAY2757556 (Larotrectinib, Vitrakvi)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 215, "start_date": "2015-09-30", "completion_date": "2025-09-29", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-11-07T14:05:19.430Z", "location_count": 18, "location_summary": "Palo Alto, California • Santa Monica, California • Pembroke Pines, Florida + 13 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02576431" }, { "nct_id": "NCT01837329", "title": "Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Tetrathiomolybdate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2013-11", "completion_date": "2019-01-11", "has_results": false, "last_update_posted_date": "2019-07-19", "last_synced_at": "2026-11-07T14:05:19.430Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01837329" }, { "nct_id": "NCT00016237", "title": "Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Cancer", "Kidney Cancer", "Lung Cancer" ], "interventions": [ { "name": "tucotuzumab celmoleukin", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-10-23", "last_synced_at": "2026-11-07T14:05:19.430Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • New York, New York", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00016237" }, { "nct_id": "NCT03241173", "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignancies" ], "interventions": [ { "name": "INCAGN01949", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Biosciences International Sàrl", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2017-10-09", "completion_date": "2019-09-17", "has_results": true, "last_update_posted_date": "2022-09-27", "last_synced_at": "2026-11-07T14:05:19.430Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03241173" }, { "nct_id": "NCT02298153", "title": "A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "NSCLC (Non-small Cell Lung Carcinoma)", "UC (Urothelial Cancer)" ], "interventions": [ { "name": "Epacadostat", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2015-01-27", "completion_date": "2017-11-08", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-11-07T14:05:19.430Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • New Haven, Connecticut • Boston, Massachusetts + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02298153" }, { "nct_id": "NCT03626545", "title": "Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small-Cell Lung" ], "interventions": [ { "name": "Canakinumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 245, "start_date": "2019-01-23", "completion_date": "2021-12-20", "has_results": true, "last_update_posted_date": "2023-08-21", "last_synced_at": "2026-11-07T14:05:19.430Z", "location_count": 6, "location_summary": "Atlanta, Georgia • Kansas City, Missouri • The Bronx, New York + 3 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "The Bronx", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03626545" }, { "nct_id": "NCT04344795", "title": "Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Colorectal Cancer", "Non Small Cell Lung Cancer", "Squamous Cell Carcinoma of Head and Neck", "Urothelial Carcinoma", "Endometrial Cancer", "Gastroesophageal Junction Adenocarcinoma", "Gastric Adenocarcinoma", "Solid Tumors With PIK3Ca Mutation" ], "interventions": [ { "name": "TPST-1495 twice daily", "type": "DRUG" }, { "name": "TPST-1495 once daily or on intermittent schedule", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tempest Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2020-05-06", "completion_date": "2024-09-25", "has_results": false, "last_update_posted_date": "2025-09-12", "last_synced_at": "2026-11-07T14:05:19.430Z", "location_count": 11, "location_summary": "Aurora, Colorado • Baltimore, Maryland • Springfield, Massachusetts + 8 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Springfield", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04344795" }, { "nct_id": "NCT06120075", "title": "A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "AB801", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2024-01-19", "completion_date": "2026-04-29", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-11-07T14:05:19.430Z", "location_count": 10, "location_summary": "Denver, Colorado • Washington D.C., District of Columbia • Atlanta, Georgia + 7 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06120075" } ] }